|Understanding COVID-19 Webinar|
Beginning in December 2019, a novel coronavirus, designated SARS-COV-2, has caused what rapidly became a global pandemic. The disease caused by SARS-COV-2, which has been designated COVID-19, appears to range from asymptomatic or mild, self-limited respiratory tract illness to progressive pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. Optimal management of this condition has not yet been established, but in addition to supportive care, various combinations of glucocorticoids, tocilizumab, anti-virals, and anti-malarial agents have been utilized with varying degrees of efficacy. Importantly, there is growing evidence of heightened vulnerability in immunocompromised patients. The impact of SARS-COV-2 and COVID-19 on the biobanking world is evolving, but likely to be profound. The purpose of this presentation will therefore be to provide a rapid, comprehensive, and relevant update on the current state of COVID-19, with attention to the epidemiology, clinical presentation, and emerging therapeutic options.
Brief Speaker Biography:
Dr. Tristan Knight is originally from Calgary, and completed medical school at the Royal College of Surgeons in Ireland (RCSI). After completing his pediatrics residency at the University of Hawaii and pediatric hematology/oncology fellowship at the Children’s Hospital of Michigan, he returned to Canada to undergo additional training in pediatric bone marrow transplant and cellular therapy at The Hospital for Sick Children (SickKids) in Toronto, where he is currently a sub-specialty fellow.